Shenlian Biological Research: High-tech animal protection company focusing on swine foot and mouth disease vaccine
China’s first pig foot-and-mouth disease synthetic peptide vaccine manufacturer.
Shenlian Biological is a new enterprise specialized in the research, development, production and sales of veterinary biological products. Its main product is swine foot and mouth disease vaccine.
Since the first successful industrialization of foot-and-mouth disease synthetic peptide vaccine in China in 2007, the company has continued to improve its R & D and innovation, and has continuously upgraded its products based on the changes in the situation of foot-and-mouth disease.The development from unit price to second price has made an important contribution to domestic animal epidemic prevention.
Revenue grew steadily, with a slight replacement in 2018.
The company’s operating income for 2016-2018 was 2.
6.8 billion yuan, 3.
02 ppm, 2.
7.5 billion, net profit attributable to mothers was 7347.
180,000 yuan, 9867.
800,000 yuan, 8758.
From 2013 to 2017, the company’s operating income and net profit maintained a steady growth. In 2018, due to the unsuccessful bidding in Heilongjiang Province and the decline in sales in Henan Province, the company’s operating income and profit both slightly increased.
Affected by the African swine fever epidemic in August 2018, the sales volume of the company’s products fell by 20% in the first half of the year when the scale of local pig breeding expanded.
86%, operating income fell 12 year-on-year.
49%, net profit drops by 10 per year.
The company performed a sensitivity analysis on the performance in 2019. Under the different assumptions that the pig breeding scale may decrease by 20%, 30%, 40%, and 50% from May to December 2019, the maximum net profit change is expected to be 15%.
The existing business is highly dependent on a single species, and the successful development of inactivated vaccines opens up room for growth.
The company’s foot-and-mouth disease type O synthetic peptide vaccine (composite 2600 + 2700 + 2800) accounted for 99% of its operating income.
97% is the main source of profit.
Although the company currently 武汉夜网论坛 has a high dependence on a single product, the company cooperated with the Lan Institute, Zhongnong Witt, and Biological Co., Ltd. to successfully develop the first domestic and foreign swine foot and mouth disease type O, A type bivalent inactivated vaccine (Re-O / MYA98 / JSCZ / 2013 strain + Re-A / WH / 09 strain).
The vaccine obtained the national first-class registration certificate for new veterinary drugs, which enriched the company’s product structure and helped to enhance the company’s market competitiveness.
The animal protection industry is under short-term pressure, but the size of the foot-and-mouth disease market is still large.
Since August 2018, the African swine fever epidemic has been happening, and the pig industry has been suffocated and the production capacity has been greatly increased.
Due to the drastic decline in the hog basal body mass, most of the companies mainly engaged in the sale of swine vaccines have experienced deterioration in performance.
As the current swine fever epidemic in Africa has not been fully controlled, we expect that it will take some time for the throughput of the breeding industry to recover, and the overall performance pressure of biological products companies throughout the year cannot be overcome. If pig prices rise in the future, the supplementary bar will gradually rise.The industry may achieve restorative growth next year.
From the standpoint of foot-and-mouth disease, our market size in 2017 has reached about 42 trillion, making it the largest veterinary vaccine.
With the launch of pig-specific A vaccines, we believe that the market penetration of foot-and-mouth disease is still increasing, and the number of pigs in stocks has stabilized. Vaccine companies will continue to grow under the general trend of product upgrades and increased penetration.
The fund-raising project built a new production line of inactivated foot-and-mouth disease vaccine, with a rich product structure.
The company intends to publicly issue no more than 50 million RMB common shares to the public this time. After allocating the issuance funds, the company will invest in the “suspension culture of FMD vaccine project”.
The investment budget for this project is 868.1 million yuan. Through the implementation of this project, the company will form an annual output of 2.
The production capacity of 500 million inactivated FMD vaccines has consolidated and increased the company’s market share in FMD vaccines.
This project is organized and implemented by Shenlian Biological Lanzhou Branch. The project construction period is 72 months, and two foot-and-mouth disease inactivated vaccine production lines, animal houses, quality inspection buildings, office buildings and related supporting facilities will be constructed.
On February 26, 2019, the production line successfully passed the GMP static acceptance and is currently in the trial production stage.
The African swine fever epidemic has caused a significant increase in the number of pigs on hand; new product sales have fallen short of expectations.